EyePoint announces data from Phase 2 PAVIA trial of DURAVYU

EyePoint Pharmaceuticals announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU, previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy, NPDR. The data demonstrated that DURAVYU has a biologic effect in patients with NPDR with a favorable safety and tolerability profile, however the trial did not meet the pre-specified primary endpoint. The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data. PAVIA topline interim results include: 86% of patients in the 3mg arm and 80% of patients in the 2mg arm demonstrated stable or improved disease at nine months versus 70% in the control arm. 0% of patients in the 3mg arm and 5% of patients in the 2mg arm worsened greater than or equal to2-step at nine months vs. 10% in the control arm. 5% of patients in the 3mg arm and 0% of patients in the 2mg arm achieved a greater than or equal to2-step improvement in DRSS score at nine months versus 5% in the control arm. Continued favorable safety and tolerability profile with no DURAVYU-related ocular or systemic serious adverse events reported. No cases of endophthalmitis or retinal vasculitis were observed.